Australia's Telix Pharmaceuticals rises on US code approval for imaging agent
RefinitivBacaan kurang dari 1 minit
** Shares of Telix Pharmaceuticals TLX rise as much as 7% to A$25.71, logging their biggest intraday pct gain since May 13
** Stock hits highest level since June 19
** TLX among top performers on the ASX 200 benchmark, which is down 0.3%
** Biopharmaceutical firm says its prostate-specific membrane antigen (PSMA) PET imaging agent, Gozellix, granted permanent healthcare common procedure coding system (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services
** Code assignment supports reimbursement for Gozellix, support clinical adoption of and expanded access to PSMA PET imaging
** Stock up 4.4% YTD
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini